摘要
目的探讨微小RNA-1180(miR-1180)在非小细胞肺癌(NSCLC)患者血清及组织中的表达情况,并分析其与临床病理特征的关系及对疾病诊断、预后评估的价值。方法选取NSCLC患者72例,另选取同期接受治疗的良性肺部疾病患者50例为研究对象。收集NSCLC患者、良性肺部疾病患者的空腹静脉血,另收集NSCLC患者手术切除的癌组织和癌旁组织。采用实时荧光定量PCR(qRT-PCR)检测血清及组织中的miR-1180的相对表达量。所有NSCLC患者均进行为期5年的随访,并统计其生存情况。结果NSCLC患者血清miR-1180的相对表达量高于良性肺部疾病患者,差异有统计学意义(P<0.05);癌组织中miR-1180的相对表达量高于癌旁组织,差异有统计学意义(P<0.05)。NSCLC患者血清及组织中miR-1180的相对表达量与性别、年龄、吸烟史、病理类型无关(P>0.05),与肿瘤大小、TNM分期、淋巴结转移以及分化程度有关(P<0.05)。血清miR-1180对NSCLC的辅助诊断价值较高,曲线下面积(AUC)为0.747,95%CI为0.580~0.914,准确度为0.754。miR-1180高表达患者的5年生存率低于miR-1180低表达患者,差异有统计学意义(P<0.05)。结论miR-1180在NSCLC的血清和癌组织中均呈异常高表达,且其表达水平与肿瘤的恶性进展密切相关。miR-1180可作为NSCLC疾病诊断和预后评估的新型生物标志物。
Objective To investigate the expression of miR-1180 in serum and tissues of non-small cell lung canceR(NSCLC),and to analyze its relationship with clinicopathological characteristics and its value foRdisease diagnosis and prognostic evaluation.Methods Seventy-two patients with NSCLC and 50 patients with benign lung disease who received treatment at the same period were selected as the study subjects.Fasting venous blood of NSCLC patients and those with benign lung diseases was collected,and the canceRtissues and adjacent tissues were collected from NSCLC patients.Quantitative real-time polymerase chain reaction(qRT-PCR)was used to detect the relative expression of miR-1180 in serum and tissues.All patients with NSCLC were followed up foR5 years,and theiRsurvival status was counted.Results The relative expression levels of miR-1180 in serum of the NSCLC patients were significantly higheRthan those in patients with the benign lung diseases(P<0.05);the relative expression of miR-1180 in the canceRtissues was significantly higheRthan that in the adjacent tissues(P<0.05).The relative expression of miR-1180 in serum and tissues of NSCLC patients was not correlated with gender,age,smoking history and pathological type(P>0.05),but was related to tumoRsize,TNM stage,lymph node metastasis and degree of differentiation(P<0.05).Serum miR-1180 had a high value in the auxiliary diagnosis of NSCLC,the area undeRthe curve(AUC)was 0.747,the 95%CI was 0.580~0.914,and the accuracy was 0.754.The 5-yeaRsurvival rate of patients with miR-1180 high expression was significantly loweRthan that of patients with low expression of miR-1180(P<0.05).Conclusion MiR-1180 is abnormally highly expressed in serum and canceRtissues of NSCLC,and its expression level is closely related to the malignant progression of tumors.MiR-1180 can be used as a new biomarkeRfoRdiagnosis and prognostic evaluation of NSCLC.
作者
孔令玉
朱天怡
KONG Lingyu;ZHU Tianyi(Department of Respiratory Medicine,General Hospital of the Northern Theater of the Chinese People′s Liberation Army,Shenyang,Liaoning,110000)
出处
《实用临床医药杂志》
CAS
2022年第3期76-80,共5页
Journal of Clinical Medicine in Practice
基金
辽宁省科学技术研究发展计划项目(2017L048)。
